Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Calcinosis | 3 | 2019 | 423 | 0.740 |
Why?
|
| Liver Diseases | 2 | 2018 | 574 | 0.460 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2019 | 7551 | 0.440 |
Why?
|
| Granuloma, Plasma Cell | 1 | 2012 | 38 | 0.420 |
Why?
|
| Iron Overload | 1 | 2010 | 35 | 0.360 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2019 | 7702 | 0.340 |
Why?
|
| Abdominal Neoplasms | 3 | 2019 | 231 | 0.340 |
Why?
|
| Diagnostic Imaging | 2 | 2019 | 1162 | 0.330 |
Why?
|
| Digestive System Abnormalities | 2 | 2019 | 38 | 0.330 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2007 | 10 | 0.310 |
Why?
|
| Intestinal Fistula | 1 | 2007 | 44 | 0.300 |
Why?
|
| Erythrocytes | 1 | 2007 | 339 | 0.280 |
Why?
|
| Melanoma | 4 | 2022 | 5317 | 0.270 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2007 | 340 | 0.250 |
Why?
|
| Image Enhancement | 3 | 2017 | 561 | 0.240 |
Why?
|
| Stomach Neoplasms | 3 | 2021 | 2278 | 0.230 |
Why?
|
| Diagnosis, Differential | 6 | 2018 | 4744 | 0.210 |
Why?
|
| Peritoneal Diseases | 2 | 2015 | 29 | 0.210 |
Why?
|
| Positron Emission Tomography Computed Tomography | 4 | 2021 | 833 | 0.200 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 4654 | 0.180 |
Why?
|
| Peritoneal Neoplasms | 2 | 2019 | 821 | 0.180 |
Why?
|
| Adrenal Cortex | 1 | 2018 | 35 | 0.170 |
Why?
|
| Bile Duct Diseases | 1 | 2019 | 45 | 0.170 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2020 | 170 | 0.170 |
Why?
|
| Esophagogastric Junction | 1 | 2021 | 543 | 0.150 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 146 | 0.150 |
Why?
|
| Pattern Recognition, Automated | 1 | 2018 | 125 | 0.150 |
Why?
|
| Cysts | 1 | 2019 | 197 | 0.150 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 565 | 0.150 |
Why?
|
| Glycolysis | 1 | 2020 | 519 | 0.150 |
Why?
|
| Carcinoma, Ductal | 1 | 2018 | 145 | 0.150 |
Why?
|
| Leiomyoma | 1 | 2018 | 145 | 0.140 |
Why?
|
| Hypercalcemia | 1 | 2017 | 137 | 0.140 |
Why?
|
| Pancreatic Diseases | 1 | 2017 | 108 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 2796 | 0.140 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2018 | 223 | 0.140 |
Why?
|
| Radiography, Abdominal | 1 | 2016 | 120 | 0.140 |
Why?
|
| Stomach | 1 | 2019 | 387 | 0.140 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 2173 | 0.130 |
Why?
|
| Intraoperative Care | 1 | 2017 | 259 | 0.130 |
Why?
|
| Wrist Joint | 2 | 2006 | 30 | 0.130 |
Why?
|
| Radiographic Image Enhancement | 1 | 2018 | 402 | 0.130 |
Why?
|
| Elbow Joint | 2 | 2006 | 42 | 0.130 |
Why?
|
| Joint Diseases | 2 | 2006 | 71 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 1 | 2017 | 408 | 0.130 |
Why?
|
| Pelvic Exenteration | 1 | 2015 | 108 | 0.130 |
Why?
|
| Uterine Neoplasms | 2 | 2019 | 545 | 0.130 |
Why?
|
| Liposarcoma | 1 | 2016 | 214 | 0.120 |
Why?
|
| Humans | 32 | 2022 | 261506 | 0.120 |
Why?
|
| Ultrasonography | 2 | 2019 | 1863 | 0.120 |
Why?
|
| Pelvic Neoplasms | 1 | 2015 | 189 | 0.120 |
Why?
|
| Patient Positioning | 1 | 2015 | 195 | 0.110 |
Why?
|
| Liver Neoplasms | 3 | 2019 | 4557 | 0.110 |
Why?
|
| Contrast Media | 2 | 2017 | 1472 | 0.110 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2015 | 255 | 0.110 |
Why?
|
| Nephrectomy | 1 | 2017 | 779 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2018 | 1226 | 0.100 |
Why?
|
| Radiopharmaceuticals | 2 | 2008 | 1301 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2010 | 6550 | 0.100 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 550 | 0.100 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1390 | 0.090 |
Why?
|
| Adult | 13 | 2021 | 77950 | 0.090 |
Why?
|
| Neoplasm Staging | 5 | 2022 | 13658 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2019 | 1341 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2022 | 4975 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 5061 | 0.080 |
Why?
|
| Technetium Tc 99m Medronate | 1 | 2008 | 23 | 0.080 |
Why?
|
| Male | 14 | 2021 | 123000 | 0.080 |
Why?
|
| Inguinal Canal | 1 | 2008 | 60 | 0.080 |
Why?
|
| Compartment Syndromes | 1 | 2008 | 30 | 0.080 |
Why?
|
| Middle Aged | 14 | 2021 | 86204 | 0.080 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 3168 | 0.080 |
Why?
|
| Technetium | 1 | 2007 | 77 | 0.080 |
Why?
|
| Female | 16 | 2021 | 141928 | 0.070 |
Why?
|
| Injections | 1 | 2008 | 285 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 1833 | 0.070 |
Why?
|
| Hand Joints | 1 | 2006 | 3 | 0.070 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2013 | 716 | 0.070 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 660 | 0.070 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 10331 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2018 | 3341 | 0.060 |
Why?
|
| Aged | 10 | 2021 | 70117 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 2843 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 3022 | 0.060 |
Why?
|
| Hand | 1 | 2004 | 170 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2020 | 1529 | 0.050 |
Why?
|
| Survival Rate | 3 | 2022 | 12221 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2020 | 7789 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 4638 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 4844 | 0.050 |
Why?
|
| Prognosis | 3 | 2018 | 21713 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 5767 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2021 | 271 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 2638 | 0.040 |
Why?
|
| Conservative Treatment | 1 | 2018 | 58 | 0.040 |
Why?
|
| Adrenalectomy | 1 | 2018 | 188 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2019 | 9180 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2022 | 2315 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 5112 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2018 | 148 | 0.030 |
Why?
|
| Macrophages | 1 | 2022 | 1304 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 29902 | 0.030 |
Why?
|
| Endometrium | 1 | 2019 | 470 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 671 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2021 | 1283 | 0.030 |
Why?
|
| Peritoneum | 1 | 2015 | 150 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 657 | 0.030 |
Why?
|
| Splenic Diseases | 1 | 2014 | 56 | 0.030 |
Why?
|
| Vipoma | 1 | 2013 | 17 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2020 | 9244 | 0.030 |
Why?
|
| Gastrinoma | 1 | 2013 | 25 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2014 | 121 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2018 | 962 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2013 | 85 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 4988 | 0.030 |
Why?
|
| Octreotide | 1 | 2013 | 118 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2013 | 108 | 0.030 |
Why?
|
| Abdomen | 1 | 2014 | 332 | 0.030 |
Why?
|
| Pelvis | 1 | 2014 | 362 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 1987 | 0.030 |
Why?
|
| Vascular Diseases | 1 | 2014 | 246 | 0.030 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2013 | 141 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 1048 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2292 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 14289 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 4892 | 0.020 |
Why?
|
| Prevalence | 1 | 2019 | 3260 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2018 | 1154 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 414 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 4367 | 0.020 |
Why?
|
| Endosonography | 1 | 2013 | 536 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 2961 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2010 | 485 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 15862 | 0.020 |
Why?
|
| Kidney | 1 | 2017 | 2146 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 15193 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 4971 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2021 | 37905 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2403 | 0.020 |
Why?
|
| Thalidomide | 1 | 2010 | 569 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3981 | 0.020 |
Why?
|
| Arm | 1 | 2008 | 147 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 6682 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2014 | 1824 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2008 | 310 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2014 | 1411 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 6009 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 3890 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2018 | 32848 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2008 | 351 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 1904 | 0.010 |
Why?
|
| Bone Diseases | 1 | 2004 | 143 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 4938 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 15179 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2004 | 479 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 17523 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 21445 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2014 | 16273 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 2341 | 0.010 |
Why?
|